Diabetes & ED: Managing Both in Edmonton & Calgary

The Diabetes-ED Connection: A Comprehensive Clinical Guide

The relationship between diabetes mellitus and erectile dysfunction is one of the most well-documented associations in all of medicine. Men with diabetes are 2 to 3 times more likely to develop ED than non-diabetic men, and they tend to develop it 10 to 15 years earlier (Malavige & Levy, 2009, Journal of Sexual Medicine). Among men with type 2 diabetes, ED prevalence ranges from 35% to 90% depending on age, disease duration, and glycemic control.

For the hundreds of thousands of men in Edmonton and Calgary managing diabetes, understanding this connection — and knowing that effective treatment exists — is essential.

> "Diabetes and erectile dysfunction are so closely linked that I often say: if you're treating diabetes without evaluating erectile function, or treating ED without evaluating metabolic health, you're missing half the picture. At ReGenesis, we address both — because the biology doesn't separate them, and neither should we." > — Dr. Lloyd Tapper, PhD, NP — Founder, ReGenesis

How Diabetes Causes Erectile Dysfunction

Diabetes damages erectile function through four interconnected pathways:

1. Endothelial Dysfunction and Vascular Damage

Chronic hyperglycemia (elevated blood sugar) damages the endothelium — the single-cell-thick inner lining of blood vessels — through several mechanisms:

• Advanced Glycation End Products (AGEs): Glucose molecules bind to proteins in blood vessel walls, forming AGEs that stiffen arteries and impair vasodilation. AGEs also quench nitric oxide (NO), the primary vasodilator required for erection (Wautier & Schmidt, 2004, *Circulation Research*).
• Oxidative stress: Hyperglycemia increases production of reactive oxygen species (ROS), which damage endothelial cells and reduce NO bioavailability
• Impaired NO synthesis: Diabetic endothelium produces less endothelial nitric oxide synthase (eNOS), directly reducing the NO signal that initiates penile smooth muscle relaxation

The result: reduced blood flow to the penis and impaired ability to achieve and maintain erection.

2. Peripheral Neuropathy

Diabetic neuropathy affects the peripheral nerves responsible for both penile sensation and the autonomic signals that trigger erection:

• Somatic neuropathy: Reduced penile sensitivity and impaired sensory feedback during sexual activity
• Autonomic neuropathy: Disrupted parasympathetic signaling that normally initiates the NO-mediated vasodilation cascade. Autonomic neuropathy also impairs the veno-occlusive mechanism (ability to trap blood in the penis), leading to erections that are achieved but not maintained.

Studies using biothesiometry (penile vibration threshold testing) have demonstrated significantly reduced penile sensation in diabetic men compared to age-matched controls (Bemelmans et al., 1995, Journal of Urology).

3. Hormonal Disruption

Diabetes — particularly type 2 diabetes associated with obesity and metabolic syndrome — is associated with significant hormonal changes:

• Lower testosterone: Multiple studies confirm that men with type 2 diabetes have total testosterone levels 30–40% lower than non-diabetic controls (Dhindsa et al., 2004, *Journal of Clinical Endocrinology & Metabolism*)
• Elevated SHBG: Further reducing bioavailable free testosterone
• Increased estrogen: Adipose tissue aromatase converts testosterone to estradiol, compounding the hormonal imbalance
• Insulin resistance: Directly impairs Leydig cell testosterone production

4. Structural Changes in Penile Tissue

Chronic diabetes alters the histological composition of the corpus cavernosum:

• Smooth muscle loss: Progressive replacement of functional smooth muscle with collagen and fibrotic tissue (Sáenz de Tejada et al., 1989, *New England Journal of Medicine*)
• Reduced elasticity: Fibrotic tissue lacks the compliance needed for expansion and engorgement
• Impaired veno-occlusive function: Structural changes compromise the ability to trap blood, resulting in "soft" or unsustained erections

Prevalence and Timeline

The statistics underscore the scale of the problem:

• 50% of men with type 2 diabetes develop ED within 5–10 years of diagnosis
• 75% of diabetic men will experience ED at some point in their lives (Hackett et al., 2018)
• ED is often the first clinical presentation of previously undiagnosed type 2 diabetes — studies estimate that 10–15% of men presenting with ED have undiagnosed diabetes (Sairam et al., 2001, *International Journal of Clinical Practice*)
• In type 1 diabetes, ED prevalence reaches 20–25% even in men under 30 (Penson et al., 2009, *Diabetes Care*)

> "I've diagnosed dozens of men with diabetes who came to me for ED treatment. They had no idea their blood sugar was elevated — their erections were the first warning sign. This is why every ED assessment at ReGenesis includes metabolic screening." > — Dr. Lloyd Tapper, PhD, NP

Treatment of Diabetic ED: A Multimodal Approach

Treating ED in diabetic men requires addressing both the erectile dysfunction and the underlying metabolic disease simultaneously.

Priority 1: Glycemic Optimization

Improving blood sugar control is the foundation of diabetic ED management:

• HbA1c reduction: A meta-analysis by Giugliano et al. (2010, *Diabetologia*) found that reducing HbA1c by 1% was associated with measurable improvement in erectile function scores
• Targets: HbA1c < 7.0% (individualized based on patient factors)
• Approach: Coordination with the patient's diabetes management team (endocrinologist, family physician) to optimize pharmacotherapy, dietary management, and monitoring

Priority 2: Cardiovascular Risk Factor Management

Because diabetic ED is primarily vasculogenic, aggressive cardiovascular risk management directly supports erectile function improvement:

• Blood pressure control (target <130/80 mmHg in diabetic patients)
• Lipid management (statin therapy per guidelines)
• Weight management (5–10% weight loss meaningfully improves both diabetes and ED)
• Smoking cessation
• Regular physical activity (150+ min/week moderate-intensity exercise)

Priority 3: ED-Specific Treatment

PDE5 Inhibitors in Diabetic Men

PDE5 inhibitors remain first-line therapy, though response rates are lower than in non-diabetic populations:

The daily low-dose tadalafil (5mg) approach has shown particular promise in diabetic men, providing consistent erectile support without the need for timing (Porst et al., 2006, European Urology).

Injectable Therapies

For diabetic men who fail PDE5 inhibitors, injectable therapy (Trimix) offers significantly higher success rates — 80–90% in diabetic populations (Coombs et al., 2012). The direct mechanism of action bypasses the impaired NO-cGMP pathway, making injectables effective even with significant vascular and neuropathic damage.

Regenerative Therapies

P-Shot (PRP therapy) and low-intensity shockwave therapy may offer particular benefit in diabetic ED by promoting neovascularization in tissue with compromised blood supply. While evidence specific to diabetic populations is still accumulating, the biological rationale is strong.

Testosterone Optimization

Given the high prevalence of hypogonadism in diabetic men, testosterone evaluation and replacement (when indicated) is an important component of comprehensive treatment. The combination of testosterone therapy + PDE5 inhibitor has been shown to convert non-responders to responders in hypogonadal diabetic men (Aversa et al., 2003).

Penile Implants

For diabetic men with severe, treatment-resistant ED, penile implant surgery offers excellent outcomes. Historically, diabetic men had slightly higher implant infection rates, but modern antibiotic-coated devices have largely eliminated this disparity (Wilson et al., 2007, Journal of Urology). Satisfaction rates in diabetic implant recipients mirror those in the general population (>90%).

Monitoring and Follow-Up

Diabetic ED requires ongoing monitoring, as both the underlying diabetes and the ED itself are progressive conditions:

• HbA1c and glucose: Quarterly monitoring
• Testosterone levels: Annual assessment
• IIEF score: Periodic reassessment of erectile function
• Cardiovascular markers: Annual lipid panel, blood pressure monitoring
• Treatment efficacy review: Dose adjustment or treatment escalation as needed

> "Managing diabetic ED is not a one-time fix — it's an ongoing partnership between the patient, the ED specialist, and the diabetes care team. At ReGenesis, we stay involved for the long term, adjusting treatment as your health evolves." > — Dr. Lloyd Tapper, PhD, NP

References

1. Malavige LS, Levy JC. Erectile dysfunction in diabetes mellitus. *Journal of Sexual Medicine*. 2009;6(5):1232-1247.
2. Giugliano F, et al. Adherence to Mediterranean diet and erectile dysfunction in men with type 2 diabetes. *Journal of Sexual Medicine*. 2010;7(5):1911-1917.
3. Dhindsa S, et al. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. *Journal of Clinical Endocrinology & Metabolism*. 2004;89(11):5462-5468.
4. Sáenz de Tejada I, et al. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men. *New England Journal of Medicine*. 1989;320(16):1025-1030.
5. Wilson SK, et al. Long-term survival of inflatable penile prostheses: single surgical group experience with 2384 first-time implants. *Journal of Urology*. 2007;178(1):247-253.
6. Hackett G, et al. Guidelines on the management of erectile dysfunction. *Journal of Sexual Medicine*. 2018;15(4):430-457.

Schedule Your Assessment

Confidential assessments available. Same-week appointments for new patients.

Ready to Take the Next Step?

Book a confidential assessment with a ReGenesis clinician.

Call 587.635.3414